IL2RB and cancer: T cells are widely known to be one of the main effector populations of immune-checkpoint therapies, it has been reported that IL2RB expression on CD8+ T cells may play a role in exhaustion in a variety of contexts including viral infection and thus this role should also be investigated within the context of cancer (16,45–53).